Globally Growing Hepatitis Vaccine Market Demands and Analysis Forecast 2020-2025 | GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, KM Biologics, LG Life Sciences, Serum Institute, Sanofi, Sinovac

Business Industry Reports Research has recently announced a report on Global Hepatitis Vaccine Market based on the Category Industry. The Hepatitis Vaccine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2025.

Global Hepatitis Vaccine Market overview:

The hepatitis B vaccine is a safe and effective vaccine that is recommended for all infants at birth and for children up to 18 years. The hepatitis B vaccine is also recommended for adults living with diabetes and those at high risk for infection due to their jobs, lifestyle, living situations, or country of birth. The Global Hepatitis Vaccine Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/280052 .

On the Basis of Product Type segment, the Hepatitis Vaccine Market is sub segmented into Hepatitis A Vaccines and Hepatitis B Vaccines. Based on End Use Industry segment, the Hepatitis Vaccine Market is segmented as Children and Adult.

There are several manufacturers of Hepatitis Vaccine in Europe and North America. In North America, the demand for Hepatitis Vaccine is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Hepatitis Vaccine Market Report 2020” @ https://www.businessindustryreports.com/buy-now/280052/single .

Top Industry News:

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV on 16 October, 2020 -- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Vocabria (cabotegravir injection and tablets) in combination with Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI) class.

Deborah Waterhouse, CEO, ViiV Healthcare, said “Today’s positive CHMP opinion marks an important step in providing a new option that changes the treatment experience for people living with HIV across Europe. Vocabria injection used in combination with Rekambys has the potential to ease the day-to-day burden of HIV by offering significantly less frequent dosing from 365 days with oral regimens to 12 or 6 treatments per year. Through our innovative R&D, we are now one step closer to offering an HIV medicine in Europe with a novel route of administration and dosing schedule compared to other therapies. We’re proud to be providing different treatment options that meet the diverse needs of the HIV community.”

If approved, cabotegravir injection used in combination with rilpivirine injection will be the first complete long-acting regimen, dosed once-monthly or once every 2-months, for virologically suppressed people living with HIV-1 across Europe. This treatment will offer people living with HIV an option with significantly less frequent dosing and comparable efficacy to daily oral regimens. Cabotegravir and rilpivirine injections are administered as two intramuscular (IM) injections in the buttocks during the same visit at a specialist clinic by a healthcare professional. Prior to the initiation of the injections, cabotegravir and rilpivirine oral tablets are taken for approximately one month (at least 28 days) to assess tolerability to the medicines.

The Marketing Authorisation Application (MAA) for cabotegravir injection and tablets is based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression), FLAIR (First Long-Acting Injectable Regimen) and ATLAS-2M studies.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/280052 .

Major Key Players:

Some of the Hepatitis Vaccine Market manufacturers involved in the market are GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, KM Biologics, LG Life Sciences, Serum Institute, Sanofi, Sinovac, Zhejiang Pukang, IMBCA, ChangSheng in World, effective mergers are some of the strategies adopted by the Hepatitis Vaccine Market manufacturers. New product launches and continuous technological innovations are the Hepatitis Vaccine Market strategies adopted by the major players.

Table of Contents:

1 Hepatitis Vaccine Product Definition
2 Global Hepatitis Vaccine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Hepatitis Vaccine Shipments
2.2 Global Manufacturer Hepatitis Vaccine Business Revenue
2.3 Global Hepatitis Vaccine Market Overview
3 Manufacturer Hepatitis Vaccine Business Introduction
3.1 GSK Hepatitis Vaccine Business Introduction
3.1.1 GSK Hepatitis Vaccine Shipments, Price, Revenue and Gross profit 2020-2025
3.1.2 GSK Hepatitis Vaccine Business Distribution by Region
3.1.3 GSK Interview Record
3.1.4 GSK Hepatitis Vaccine Business Profile
3.1.5 GSK Hepatitis Vaccine Product Specification
3.2 NCPC Hepatitis Vaccine Business Introduction
3.2.1 NCPC Hepatitis Vaccine Shipments, Price, Revenue and Gross profit 2020-2025
3.2.2 NCPC Hepatitis Vaccine Business Distribution by Region
3.2.3 Interview Record
3.2.4 NCPC Hepatitis Vaccine Business Overview
3.2.5 NCPC Hepatitis Vaccine Product Specification
3.3 MERCK Hepatitis Vaccine Business Introduction
3.3.1 MERCK Hepatitis Vaccine Shipments, Price, Revenue and Gross profit 2020-2025
3.3.2 MERCK Hepatitis Vaccine Business Distribution by Region
3.3.3 Interview Record
3.3.4 MERCK Hepatitis Vaccine Business Overview
3.3.5 MERCK Hepatitis Vaccine Product Specification
3.4 Bio Kangtai Hepatitis Vaccine Business Introduction
3.5 Dynavax Hepatitis Vaccine Business Introduction
3.6 Hissen Hepatitis Vaccine Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.